Clovis Oncology’s Rubraca (Rucaparib) Receives EU Approval for Maintenance Treatment of Relapsed Ovarian Cancer (OC) in Adults
Clovis Oncology Reports Results of Rubraca (rucaparib) in P-III ARIEL3 Study for Advanced Ovarian Cancer
Shots:
- The approval is based on P-III ARIEL3 study results assessing Rubraca (600mg, bid) vs PBO in 564 women in a ratio (2:1) with a recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in complete or partial response to PT-based CT
- P-III ARIEL3 study results: PFS events (62% vs 88%); mPFS (10.8mos. vs 5.4mos.); In tBRCA Group: PFS events (52% vs 85%); mPFS (16.6mos. vs 5.4mos.), CR 7%; Tumor response (18% vs 8%)
- Rubraca (rucaparib) is an inhibitor of PARP1, PARP2 and PARP3 targeted as a monothx or in combination for multiple tumor types, including ovarian, metastatic castration-resistant prostate and bladder cancers
Click here to read full press release/ article | Ref:ClovisOncology | Image: Innovation News